UB Paderborn / Katalog / Suche / in CDI

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study

The lancet oncology, 2017-05, Vol.18 (5), p.640-653

2017

Link zum Volltext

Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022-01, Vol.25 (1), p.197-206

2022

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab in combination with 5‐fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2‐positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group

International journal of cancer, 2021-09, Vol.149 (6), p.1322-1331

2021

Link zum Volltext

Verfügbarkeit prüfen

Pazopanib with 5‐FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase‐II study—The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO‐STO‐0510

International journal of cancer, 2022-03, Vol.150 (6), p.1007-1017

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of ramucirumab combination chemotherapy as second‐line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first‐line therapy

International journal of cancer, 2024-06, Vol.154 (12), p.2142-2150

2024

Link zum Volltext

Verfügbarkeit prüfen

Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2019-07, Vol.22 (4), p.803-816

2019

Link zum Volltext

Verfügbarkeit prüfen

Association between oncologists' death anxiety and their end‐of‐life communication with advanced cancer patients

Psycho-oncology (Chichester, England), 2023-06, Vol.32 (6), p.923-932

2023

Link zum Volltext

Verfügbarkeit prüfen

Reply to F. Salani et al

Journal of clinical oncology, 2024-05, Vol.42 (15), p.1862

2024

Link zum Volltext

Verfügbarkeit prüfen

The efficacy of treatment options for patients with gastric cancer and peritoneal metastasis

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2019-11, Vol.22 (6), p.1226-1237

2019

Link zum Volltext

Verfügbarkeit prüfen

Anastomotic leak predicts diminished long-term survival after resection for gastric and esophageal cancer

Surgery, 2016-07, Vol.160 (1), p.191-203

2016

Link zum Volltext

Verfügbarkeit prüfen

Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer

Oncology research and treatment, 2018-01, Vol.41 (5), p.272-280

2018

Link zum Volltext

Verfügbarkeit prüfen

German, Austrian, and Swiss guidelines for systemic treatment of gastric cancer

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2024-01, Vol.27 (1), p.6-18

2024

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022-05, Vol.25 (3), p.586-597

2022

Link zum Volltext

Verfügbarkeit prüfen

A FDG-PET radiomics signature detects esophageal squamous cell carcinoma patients who do not benefit from chemoradiation

Scientific reports, 2020-10, Vol.10 (1), p.17671-17671, Article 17671

2020

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy in Squamous Cell Cancer of the Esophagus

Current oncology (Toronto), 2022-03, Vol.29 (4), p.2461-2471

2022

Link zum Volltext

Verfügbarkeit prüfen

Impact of Postoperative Chemotherapy in Patients with Gastric/Gastroesophageal Adenocarcinoma Treated with Perioperative Chemotherapy

Current oncology (Toronto), 2022-03, Vol.29 (3), p.1983-1996

2022

Link zum Volltext

Verfügbarkeit prüfen

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

European journal of cancer (1990), 2011-10, Vol.47 (15), p.2306-2314

2011

Link zum Volltext

Verfügbarkeit prüfen

Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2021-07, Vol.24 (4), p.970-977

2021

Link zum Volltext

Verfügbarkeit prüfen

Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma

Pharmaceuticals (Basel, Switzerland), 2021-02, Vol.14 (2), p.151

2021

Link zum Volltext

Verfügbarkeit prüfen

EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group

BMC cancer, 2019-05, Vol.19 (1), p.494-494, Article 494

2019

Link zum Volltext

Verfügbarkeit prüfen

Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial

Tumor biology, 2018-03, Vol.40 (3), p.1010428318764007-1010428318764007

2018

Link zum Volltext

Verfügbarkeit prüfen

Sodium Thiosulfate Reduces Acute Kidney Injury in Patients Undergoing Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy with Cisplatin: A Single-Center Observational Study

Annals of surgical oncology, 2022-01, Vol.29 (1), p.152-162

2022

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel and Continuous-Infusion Fluorouracil Versus Epirubicin, Cisplatin, and Fluorouracil for Advanced Gastric Adenocarcinoma: A Randomized Phase II Study

Journal of clinical oncology, 2005-01, Vol.23 (3), p.494-501

2005

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study

Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial

Pazopanib with 5‐FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase‐II study—The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO‐STO‐0510

Efficacy of ramucirumab combination chemotherapy as second‐line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first‐line therapy

Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer

Association between oncologists' death anxiety and their end‐of‐life communication with advanced cancer patients

Reply to F. Salani et al

The efficacy of treatment options for patients with gastric cancer and peritoneal metastasis

Anastomotic leak predicts diminished long-term survival after resection for gastric and esophageal cancer

Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer

Phase III randomized, double‐blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum‐containing regimen (RADPAC)

German, Austrian, and Swiss guidelines for systemic treatment of gastric cancer

Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)

A FDG-PET radiomics signature detects esophageal squamous cell carcinoma patients who do not benefit from chemoradiation

Immunotherapy in Squamous Cell Cancer of the Esophagus

Impact of Postoperative Chemotherapy in Patients with Gastric/Gastroesophageal Adenocarcinoma Treated with Perioperative Chemotherapy

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study

Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma

Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial

Sodium Thiosulfate Reduces Acute Kidney Injury in Patients Undergoing Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy with Cisplatin: A Single-Center Observational Study

Docetaxel and Continuous-Infusion Fluorouracil Versus Epirubicin, Cisplatin, and Fluorouracil for Advanced Gastric Adenocarcinoma: A Randomized Phase II Study

Suchergebnisse filtern